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Objective: Glioblastoma multiforme (GBM) is a highly malignant brain tumor with a poor prognosis. MicroRNAs
(miRNAs) are a class of small non-coding RNAs, approximately 21–25 nucleotides in length. Recently, some
researchers have demonstrated that plasma miRNAs are sensitive and specific biomarkers of various cancers. The
primary aim of the study is to investigate whether miRNAs present in the plasma of GBM patients can be used as
diagnostic biomarkers and are associated with glioma classification and clinical treatment.
Materials and Methods: Plasma samples were attained by venipuncture from 50 patients and 10 healthy donors.
Plasma levels of miRNAs were determined by real-time quantitative polymerase chain reaction.
Results: The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared
to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity.
However, these three miRNAs were not significantly changed in patients with other brain tumors such as
meningioma or pituitary adenoma. Furthermore, the plasma levels of these three miRNAs in GBM patients treated
by operation and chemo-radiation almost revived to normal levels. Finally, we also demonstrated that miR-128 and
miR-342-3p were positively correlated with histopathological grades of glioma.
Conclusions: These findings suggest that plasma specific miRNAs have potential use as novel biomarkers of glioma
and may be useful in clinical management for glioma patients.
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Glioblastoma multiforme (GBM, a grade IV glioma) is a
primary brain tumor that is highly malignant, and the
patients diagnosed with GBM remain poor prognosis
despite implementation of intensive therapeutic strat-
egies and clinical efforts. To date, the diagnosis of GBM
before clinical treatment is mainly by computer tomog-
raphy (CT) and nuclear magnetic resonance imaging
(MRI). However, they are expensive and difficult to
spread. Therefore, it is an urgent need to find new
approaches to early diagnose GBM and monitor disease
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reproduction in any medium, provided the orMicroRNAs (miRNAs) are a large class of small non-
coding RNAs that regulate gene expression at the post-
transcriptional level [1]. MiRNAs are thought to regulate
expression of more than 30% of messenger RNAs and
play a viral role in many physiological and pathological
processes such as cellular proliferation, differentiation,
apoptosis, carcinogenesis, cancer cell invasion [2-4].
Additionally, more and more researchers also found that
circulating miRNAs of plasma or serum (extracellular
miRNAs) could be used as potential biomarkers for de-
tection, identification, and classification of cancers and
other diseases because (1) miRNAs expression is spe-
cific in different tissues [5], (2) the expression levels of
miRNAs are changed in cancers or other diseases
[6,7], (3) miRNAs of plasma or serum is a remarkably
stable form and can be detected in plasma [8].
Baraniskin et al. found that miRNAs in cerebrospinal
fluid (CSF) could be referred to as biomarkers for diag-
nosis of glioma [9]. However, it is difficult to attain CSF.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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miRNAs in peripheral blood also may be suitable biomar-
kers for GBM [10]. But miRNAs of blood cells may inter-
fere with the accuracy of the results. Thus, miRNAs in
plasma or serum could be developed as a novel class of
blood-based biomarker to diagnose and monitor glioma.
Up to now, previous studies have documented that a
number of miRNAs, including miR-21, miR-128, miR-15b,
miR-221/miR-222, miR-181a/b/c and miR-342-3p, were
dysregulated in glioma tissue [10-14]. These miRNAs play
a vital role in anti-apoptosis, proliferation, invasion, and
angiogenesis of glioma cells. In this present study, there-
fore, these miRNAs were chosen and detected in plasma
samples of glioma patients as well as healthy controls. The
primary aim of the study was to investigate whether GBM-
associated miRNAs in plasma could be used as diagnostic
biomarker of glioma patients, and whether these miRNAs
significantly altered could reflect the glioma classification,
stage of disease and effect of clinical treatment.
Methods
Ethics statement
The study was approved by Research Ethics Committee of
Tianjin Huanhu Hospital. All clinical samples described
here were gained from patients who had given informed
consent and stored in the hospital database.
Clinical samples
Plasma samples for miRNAs detection were collected from
patients with pathologically confirmed glioma (grade II-IV)
(n = 30), pituitary adenoma (n = 10) and meningioma (n =
10) before surgery at Department of Neurosurgery, Tianjin
Huanhu Hospital from January, 2011 to April, 2012. In
addition, plasma samples of GBM patients (n = 10) were
obtained in preoperation, two weeks after surgery and a
month after X-ray radiotherapy and temozolomide chemo-
therapy, respectively. The detailed characteristics of these
patients are shown in Table 1. Plasma samples from
healthy donors (n = 10) were obtained. The blood samples
were obtained and centrifuged for 10 min at 1,500 g within
2 h after collection, and the supernatant was removed to
RNase-free tubes and further centrifuged for 10 min atTable 1 Characteristic of brain tumors patients
Brain tumors
Tumor types Glioma
Grade II Grade III Grad
Sample Size n=10 n=10 n=10
Average Age 47.9 45.9 51.3
Range 25-71 25-72 27-75
Sex
Male 5 4 5
Female 5 6 512,000 g and 4°C to remove cells and debris. Plasma was
stored at −80°C until further processing.
MiRNAs isolation and quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR)
MiRNAs were extracted from 400 μL of plasma using
the miRcute miRNA isolation kit (Tiangen biotech C,
LTD. Beijing) according to the manufacturer’s protocol.
Briefly, 400 μL Lysis Solution and 200 fmol mmu-miR-
295 mimics (Qiagen, USA) were added into 400 μL
plasma and incubated for 5 min and centrifuged for 10
min at room temperature. The supernatant was removed
and added 200 μL chloroform, and then the mixture was
centrifuged at 12,000 g for 15 min. Aqueous phase was
transferred to an absorption column in the miRNA ex-
traction kit. MiRNAs were absorbed in the column and
then solution C was added to remove the protein, the
waste solution was removed by centrifuge. The column
was washed with wash solution in the kit for twice, and
finally the miRNAs were dissolved in 20 μL RNase-free
water. Subsequently, the miRNA samples were stored at
−80°C. MiRNAs was quantified using the NanoDrop
1000 (NanoDrop, Wilmington, DE).
A SYBR Green-based quantitative RT-PCR assay was
performed in order to quantify miRNAs in isolated plasma
samples. For each target, 2 μg of plasma miRNAs for each
subjects was reversely transcribed in 10 μL reaction sys-
tem containing: 1 μL miScript Reverse Transcriptase Mix,
4 μL 5×miScript RT Buffer and 0.5 μL (100 pmol/μL) pri-
mer (sequences shown in Table 2), and the mixture was
added with RNase-free water to 10 μL volume. The mix-
ture was incubated at 65°C for 10 min, 42°C for 60 min,
followed by 70°C for 10 min. Real-time PCR was employed
with a SYBR Premix Ex Taq (TaKaRa, Dalian, China), all
specific primers for miRNAs were synthesized by AuGCT
DNA-SYN Biotechnology (Beijing, China) (sequences
shown in Table 2). Real-time PCR reactions were carried
out in a total volume of 20 μL reaction mixture containing:
1 μL of RT product mixed with 0.5 μL (10 pmol/μL) for-
ward and reverse primer respectively, 10 μL of SYBR Pre-
mix Ex Taq and 8 μL of water. The procedure for PCR was







Table 2 The sequence of synthetic primers of PCR, RT and
single-stranded miRNAs









































mmu-miRNA-295 Forward primer TGCGGAAAGTGCTACTACTTTTG
Reverse primer CCAGTGCAGGGTCCGAGGT
mmu-miRNA-295 RNA AAAGUGCUACUACUUUUGAGUCU
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were performed in triplicate using ABI 7500 PCR system
(ABI, USA) and was normalized by spiked-in mmu-miR-
295 expression for plasma (Previous research has confirmed
mmu-miR-295 is absent in normal human serum [15]).
Statistical analysis
The statistical analysis was performed by SPSS version
13.0. The Mann–Whitney test was used to assess the dif-
ferences between the healthy group and GBM patients. A
P value of less than 0.05 was considered statistically sig-
nificant. The Bonferroni correction was applied for mul-
tiple comparisons for between normal control group,
glioma II, III and IV grade, or different brain tumors, P-
values are significant at the 0.008 level adjusted for mul-
tiple comparisons with Bonferroni correction. The relative
levels of microRNA were quantified using the 2-△△Ct
method. Receiver operating characteristic (ROC) curves
were generated to assess the power of each miRNA to dis-
tinguish GBM patients from healthy group.Results
The predictive value of plasma miR-21, miR-128 and miR-
342-3p in GBM patients
We obtained 10 blood samples from patients with a histo-
pathologically confirmed diagnosis of GBM and 10 healthy
volunteers with a matched distribution of age and sex
served as controls. In our studies, nine miRNAs (Table 3:
miR-21, miR-128, miR-15b, miR-221, miR-222, miR-342-
3p, miR-181a, miR-181b and miR-181c) were selected to
examine their potential to serve as biomarkers for
GBM. We analyzed whether these candidate miRNAs
could serve as circulating markers by comparing their
plasma levels between GBM patients and normal controlsTable 3 Candidate miRNAs for investigation in the
plasma of GBM
miRNA Previous association with Glioblastoma
miR-21 High levels of miR-21 were first reported in glioblastoma
tumors and cell lines compared to normal
brain tissue [11,12].
miR-15b Down-regulated in glioblastoma tissue compared to
normal brain tissue [14]
miR-222/221 Increased expression in glioblastoma tissue compared to
normal brain tissue [13]
miR-128 Down-regulated in glioblastoma tissue compared to
normal brain tissue [13]
miR-181a/b/c Down-regulated in glioblastoma tissue compared to
normal brain tissue [13]
miR-342-3p Expression level decreased in blood of the glioblastoma
patients compared to th heathy donors [10]
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sion was significantly higher in the GBM group than in
the control group (P < 0.001, Figure 1A), while miR-128
and miR-342-3p were remarkably lower in the GBM
group (P < 0.001, Figure 1C and E). To determine whether
the three plasma miRNAs could specifically and sensitively
discriminate GBM from healthy controls, ROC curves
were constructed. The ROC curves analysis showed that
at the optimal cut-off, plasma miR-21 had a 90%Figure 1 Relative expression levels of miR-21, miR-128 and miR-342-3
analysis based on expression of each miRNA in plasma. (A, B, C) Expre
mmu-miR-295 and analyzed using 2-△△Ct method. Statistically significant differ
miR-21 are significantly higher in GBM samples than in control samples (P < 0
GBM samples than in control samples (P < 0.001). (B) The AUC for miR-21 was
(D,F) The AUC for miR-128 or miR-342-3p was 1.000 (95% CI: 1.000 – 1.000) wsensitivity and a 100% specificity and the area under the
ROC curve (AUC) was 0.9300 [95% confidence interval
(CI): 0.7940-1.066)] (Figure 1B); miR-128 and miR-342-3p
had a 90% sensitivity and a 100% specificity and AUC was
1.000 (95% CI: 1.000-1.000), respectively (Figure 1D and F).
But plasma levels of miR-15b, miR-221, miR-222 and miR-
181a/b/c did not show significant difference between con-
trols and GBM patients (P > 0.05) (Figure 2A, B, C, D, E
and F).p in plasma from healthy controls and GBM patients, ROC curve
ssion levels of the miR-21, miR-128 and miR-342-3p are normalized to
ences were determined using the Mann–Whitney U test. Plasma levels of
.001), and levels of miR-128 and miR-342-3p are significantly lower in
0.9300 (95% CI: 0.7940-1.066) with 90.0% sensitivity and 100% specificity.
ith 90.0% sensitivity and 100% specificity.
Figure 2 Expression levels miR-15b, miR-221/222, miR-181a/d/c levels in plasma of healthy controls and GBM patients. All these miRNAs
are normalized to mmu-miR-295 and analyzed using 2-△△Ct method. Statistically significant differences were determined using the Mann–Whitney
U test. There was no significant difference between controls and GBM patients (P > 0.05).
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miR-342-3p with histopathological grade of glioma
In order to further explore the relationship between the
plasma levels of miR-21, miR-128 and miR-342-3p and
histopathological grade of glioma, we collected plasma
samples from a group of normal cohorts (n =10), grade
II (n = 10), grade III (n = 10) and GBM patients (grade
IV) (n = 10) and detected the levels of miR-21, miR-128
and miR-342-3p using real-time PCR. Plasma level ofmiR-21 was significantly higher in grade II, grade III and
GBM samples than in control samples (P < 0.001
Figure 3A), but we failed to find a relationship between its
expression and clinical grades of glioma. Our data also
showed a much lower level of miR-128 in high grades gli-
oma (grade IV and III) than low grades glioma (grade II)
(Figure 3B, P < 0.008); however, no difference was found
between grade III and grade IV (Figure 3B, P > 0.008).
There are significant difference in expression levels of miR-
Figure 3 The relationship between the plasma levels of miR-21, miR-128 and miR-342-3p and classification of glioma. (A) Levels of
miR-21 were up-regulated in grade II in comparison with control cohorts and much higher in grade III cohorts than in grade II cohorts, however
there were no significant difference between glioblastoma patients (grade IV) and grade III cohorts or grade II cohorts. (B) Levels of miR-128 were
significantly lower in grade II cohorts than in normal cohorts, much lower in grade III cohorts and in glioblastoma patients than in grade II
cohorts (P < 0.001), there were no significant difference between glioblastoma patients and grade III cohorts. (C) Levels of miR-342-3p were
significant difference among all formation. *P<0.008 in comparison with normal, #P < 0.008 in comparison with glioma II, △P < 0.008 in
comparison with glioma III.
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Plasma level of miR-342-3p was notably decreased in gli-
oma with ascending tumor grades.
Changes of miR-21, miR-128 and miR-342-3p levels in
plasma samples of GBM patients after operation and
chemo-radiation
We chose 10 GBM patients and collected their plasma in
preoperation, postoperation and after chemo-radiation.
We found that the levels of miR-21 did not show signifi-
cant difference between cohorts of preoperation and post-
operation (P = 0.393), however, the levels of miR-21 was
observably reduced after chemo-radiation (P < 0.001,
Figure 4A). Furthermore, our data also revealed that the
levels of miR-128 and miR-342-3p were markedly distinct
between cohorts of preoperation, postoperation and
chemo-radiation (P < 0.001, Figure 4B and C). Afterpatients were treated by operation and chemo-radiation,
the levels of miR-21, miR-128 and miR-342-3p revived to
normal levels and did not differ significantly between
chemo-radiation cohort and controls (P > 0.008).
The expression levels of plasma miR-21,miR-128 and miR-
342-3p specifically correlated with glioma
To evaluate weather levels of plasma miR-21, miR-128
and miR-342-3p are specifically correlated with glioma,
we selected a group of normal cohorts (n = 10), men-
ingioma cohorts (n = 10), pituitary adenoma cohorts
(n = 10) and glioma cohorts (n = 30). We found that
plasma levels of miR-21 were significantly higher in gli-
oma samples than in normal control samples (P < 0.001,
Figure 5A), and levels of miR-128 and miR-342-3p were
significantly lower in glioma samples than in control
samples (P < 0.001, Figure 5B). In addition, there was
Figure 4 The miR-21, miR-128 and miR-342-3p expression in normal control (n = 10), preoperation (n =10), postoperation (n = 10) and
chemo-radiation (n = 10) plasma samples. (A) Plasma levels of miR-21 are not significantly different between preoperative and postoperative
patients, but levels of miR-21 are significantly lower in chemo-radiation cohorts. (B) and (C) Levels of miR-128 and miR-342-3p showed significant
difference between cohorts of preoperation and postoperation and chemo-radiation. *P < 0.008 in comparison with normal, # P < 0.008 in
comparison with preoperation, △P < 0.008 in comparison with postoperation.
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oma patients or pituitary tumor patients (P > 0.008,
Figure 5C). The data suggest that the three miRNAs are
specifically associated with glioma.
Discussion
In the study, our results showed that miR-21 was up-
regulated in plasma samples of human glioma tumors
compared to healthy controls, whereas miR-128 and miR-
342-3p were down-regulated. ROC analysis demonstrated
the sensitivity and specificity of miR-21, miR-128 and
miR-342-3p for GBM diagnosis. In order to further inden-
tify the relationship between plasma level of the three
miRNAs and classification and treatment effect of glioma,
we next performed statistical analysis of our miRNAs ex-
pression data. There was a significant difference in plasma
levels of miR-128 between the earlier stages (grade II) and
the later subgroups (grade III and IV). Plasma level of
miR-342-3p was notably decreased in glioma withascending tumor grades. Expression levels of three miR-
NAs in plasma samples of patients treated reached levels
comparable with control subjects. Additionally, the three
miRNAs can specifically discriminate glioma from other
brain tumor such as pituitary adenoma and meningioma.
MiRNAs were firstly discovered in 1993 when Lee et al.
studied regulation of developmental timing in Caenorhabdi-
tis and reported a small RNA, lineage- definicient-4 (lin-4)
[16]. To date, more than 1 000 miRNAs in human have
been discovered according to miRBase sequence Database
Release 14 (www.mirbase.org/). MiRNAs represent ap-
proximately 1% of the eukaryotic transcriptome. They play
key regulatory roles in a diverse range of pathway, includ-
ing tumorigenesis and progression of cancer. Furthermore,
variation of specific miRNAs in plasma offers the potential
for detection, subtype and prognosis determination.
MiR-21 level is markedly elevated in human GBM
tumor tissues [11-13]. It targets multiple components and
plays an anti-apoptotic function in GBM. We found that
Figure 5 Plasma levels of miR-21, miR-128 and miR-342-3p in normal cohorts, meningioma cohorts, pituitary adenoma cohorts and
glioma cohorts. (A) Plasma levels of miR-21 are significantly increased in glioma samples compared to control samples, (B) and (C) levels of
miR-128 and miR-342-3p are markedly reduced in glioma samples compared to control samples. But there was no significant difference between
controls and meningioma patients or pituitary adenoma patients (P > 0.05). *P < 0.008 in comparison with normal, # P < 0.008 in comparison
with meningioma, △P < 0.008 in comparison with pituitary adenoma.
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than in controls, which is consistent with the finding of
miR-21 with significant levels in CSF sample and tissue
from patients with glioma [9,11]. Furthermore, although
circulating miR-21 is reduced in postoperation compared
to preoperation, no significant difference existed. MiR-21
is observably decreased after further treatment with
chemo-radiaton. Thus, these data suggest a possible asso-
ciation between miR-21 and treatment effect.
The expression level of brain-enriched miRNA-128 in
glioma tissues is inversely correlated with tumor grade
and function as a tumor suppressor [17]. Similarly, we
found that expression level of miR-128 in plasma of GBM
patients was also decreased and negatively relevant to high
and low grade glioma, just same as the tendency reflected
in the test results of glioma tissues. But another research
reported that miR-128 was up-regulated in peripheral
blood of GBM patients [10]. The reason may be that miR-
NAs contained blood cells cause the difference. Our dataalso revealed that miR-128 is up-regulated after glioma
patients were treated, so miR-128 may be associated with
curative effect.
To date, little is known whether miR-342-3p is dysre-
gulated in glioma tissues and has an effect on glioma de-
velopment. Roth et al. reported that miR-342-3p was
down-regulated in peripheral blood of GBM patients
[10]. In the present study, our results also showed that
the expression level of miR-342-3p is reduced in the
plasma of glioma patients and also inversely correlated
with glioma grade. In addition, we assessed the expres-
sion of miR-342-3p by real-time PCR in the group of
patients who had been treated by operation and chemo-
radiation. miR-342-3p is significantly increased and there
are no differences between normal, control plasma and
plasma sampling received therapies. All these results re-
veal that plasma-derived miR-342-3p may be a suitable
biomarker which can function as diagnosis, classification
and therapeutic effect.
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remains to be fully elucidated. Some researchers have
demonstrated that miRNAs in plasma are released from
cells in membrane-bound vesicles which are named
microvesicles (exosomes). These exosomes come from
multivesicular bodies and are released by exocytosis and
also can be shed by outward budding of the plasma
membrane [18-21]. These early reports are confirmed
by which cultured cells release exosomes containing
miRNAs [22-24]. Similarly, one study has also demon-
strated that microvesicles (exosomes) containing miRNAs
are released from glioblastoma cells and the size of them is
from 50 to 500 nm [25]. The other two researches have
revealed most of the extracellular miRNAs is bound to
protein and form complexes rather than vesicles [26,27].
Comprehensive previous researches, we preliminarily
speculate that miRNAs in the plasma of patients with gli-
oma derive from glioma cells because (1) blood brain bar-
rier (BBB) is partly destroyed in patients with glioma; (2)
exosomes or complexes may be through the BBB by un-
known mechanisms. It is necessary to further investigate if
microvesicles encapsulation is the only mechanism for
miRNAs in plasma with glioma or if other potentially
more predominant mechanisms exist. One interesting
point we observed in our study and other studies is that
the expression level of some miRNAs is different in differ-
ent body fluids. For example, our results found that miR-
15b in plasma doesn’t dysregulate, but another study has
indicated that it is significantly increased in CSF from
patients with glioma compared to samples from control
patients [9]. Because BBB exists, it is necessary to system-
atically explore the origin of plasma miRNAs of glioma
patients and find the relationship between miRNAs of
tumor cells and that of plasma.
In summary, our results demonstrate cell-free miR-21,
miR-128 and miR-342-3p of plasma are specificity and
sensitivity for diagnosis of GBM, suggesting that these
miRNAs may be used as non-invasive biomarkers in
GBM. Moreover, our data also find that particular
miRNAs have a strong correlation with classification
and clinical course and aid in therapeutic decisions for
glioma patients through detecting plasma.
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